Jie Zhu1, Venkata Bandi2, Shengyang Qiu1, David J Figueroa3, Jilly F Evans3, Neil Barnes4, Kay K Guntupalli2, Peter K Jeffery5. 1. Lung Pathology Unit, Department of Respiratory Medicine, Imperial College London, London, England. 2. Department of Medicine, Baylor College of Medicine, Ben Taub General Hospital, Houston, TX. 3. Department of Pharmacology, Merck & Co Inc, West Point, PA. 4. Department of Respiratory Medicine, Barts and The London Hospital, London, England. 5. Lung Pathology Unit, Department of Respiratory Medicine, Imperial College London, London, England. Electronic address: p.jeffery@imperial.ac.uk.
Abstract
BACKGROUND: Cysteinyl leukotriene 1 (CysLT1) receptor expression is known to be increased in the airway mucosa of patients with asthma, especially during exacerbations; however, nothing is known of its expression in COPD. METHODS: We applied immunohistochemistry and in situ hybridization to endobronchial biopsies to determine inflammatory cell CysLT1 receptor protein and mRNA expression in the following: (1) 15 nonsmoker control subjects (NSC), (2) 16 smokers with moderate to severe COPD in its stable phase (S-COPD), and (3) 15 smokers with COPD hospitalized for a severe exacerbation (SE-COPD). RESULTS: The total number of bronchial mucosal inflammatory cells (CD45+) and those expressing CysLT1 receptor protein were significantly greater in SE-COPD (CysLT1 receptor protein: median [range] = 139 [31-634]) as compared with S-COPD (32 [6-114]) or NSC (16 [4-66]) (P < .001 for both). CysLT1 receptor gene expression showed similar differences. A greater proportion of CD451 cells expressed CysLT1 receptor protein in SE-COPD (median [range] = 22% [8-81]) compared with S-COPD (10% [4-32]) (P < .03) or NSC (7% [1-19]) (P < .002). In SE-COPD, the relative frequencies of CysLT1 receptor-expressing cells were as follows: tryptase1 mast cells > CD681 monocytes/macrophage > neutrophils > CD201 B lymphocytes = EG21 eosinophils. Moreover, there were positive correlations between the numbers of cells expressing CysLT1 receptor protein and the numbers of CD451 cells (r = 0.78; P < .003) and tryptase1 mast cells (r = 0.62; P < .02). CONCLUSIONS: Bronchial mucosal CysLT1 receptor-positive inflammatory cells are present in the bronchial mucosa in COPD in greatest number in those experiencing a severe exacerbation.
BACKGROUND:Cysteinyl leukotriene 1 (CysLT1) receptor expression is known to be increased in the airway mucosa of patients with asthma, especially during exacerbations; however, nothing is known of its expression in COPD. METHODS: We applied immunohistochemistry and in situ hybridization to endobronchial biopsies to determine inflammatory cell CysLT1 receptor protein and mRNA expression in the following: (1) 15 nonsmoker control subjects (NSC), (2) 16 smokers with moderate to severe COPD in its stable phase (S-COPD), and (3) 15 smokers with COPD hospitalized for a severe exacerbation (SE-COPD). RESULTS: The total number of bronchial mucosal inflammatory cells (CD45+) and those expressing CysLT1 receptor protein were significantly greater in SE-COPD (CysLT1 receptor protein: median [range] = 139 [31-634]) as compared with S-COPD (32 [6-114]) or NSC (16 [4-66]) (P < .001 for both). CysLT1 receptor gene expression showed similar differences. A greater proportion of CD451 cells expressed CysLT1 receptor protein in SE-COPD (median [range] = 22% [8-81]) compared with S-COPD (10% [4-32]) (P < .03) or NSC (7% [1-19]) (P < .002). In SE-COPD, the relative frequencies of CysLT1 receptor-expressing cells were as follows: tryptase1 mast cells > CD681 monocytes/macrophage > neutrophils > CD201 B lymphocytes = EG21 eosinophils. Moreover, there were positive correlations between the numbers of cells expressing CysLT1 receptor protein and the numbers of CD451 cells (r = 0.78; P < .003) and tryptase1 mast cells (r = 0.62; P < .02). CONCLUSIONS: Bronchial mucosal CysLT1 receptor-positive inflammatory cells are present in the bronchial mucosa in COPD in greatest number in those experiencing a severe exacerbation.
Authors: D J Figueroa; R M Breyer; S K Defoe; S Kargman; B L Daugherty; K Waldburger; Q Liu; M Clements; Z Zeng; G P O'Neill; T R Jones; K R Lynch; C P Austin; J F Evans Journal: Am J Respir Crit Care Med Date: 2001-01 Impact factor: 21.405
Authors: H Shirasaki; E Kanaizumi; K Watanabe; T Matsui; J Sato; S Narita; M Rautiainen; T Himi Journal: Clin Exp Allergy Date: 2002-07 Impact factor: 5.018
Authors: Ana Lukic; Jie Ji; Helena Idborg; Bengt Samuelsson; Lena Palmberg; Susanne Gabrielsson; Olof Rådmark Journal: J Lipid Res Date: 2016-07-19 Impact factor: 5.922
Authors: Magnus Bäck; William S Powell; Sven-Erik Dahlén; Jeffrey M Drazen; Jilly F Evans; Charles N Serhan; Takao Shimizu; Takehiko Yokomizo; G Enrico Rovati Journal: Br J Pharmacol Date: 2014-07-12 Impact factor: 8.739
Authors: Jie Zhu; Patrick Mallia; Joseph Footitt; Yusheng Qiu; Simon D Message; Tatiana Kebadze; Julia Aniscenko; Peter J Barnes; Ian M Adcock; Onn M Kon; Malcolm Johnson; Marco Contoli; Luminita A Stanciu; Alberto Papi; Peter K Jeffery; Sebastian L Johnston Journal: J Allergy Clin Immunol Date: 2020-04-10 Impact factor: 10.793